Events

LSX World Congress w/ Jackie Hunter

Drug Discovery and Development in the Era of AI and Analytics

The life science sector has struggled for years with expensive, inefficient drug discovery and high failure rates in drug development. Now, new technologies like artificial intelligence, machine learning, and data analytics promise to revolutionise biopharma R&D with in-silico drug design, sophisticated analysis of highly complex data sets, and an accelerated path through the clinic and to market. But what is the reality on the ground behind the buzz? Just how remote is the R&D model promoted by AI evangelists, and what are the major hurdles that R&D teams and innovators still must overcome if that model is to become reality? A panel of biopharma R&D transformers discuss the potential of artificial intelligence and data-driven technologies to create a new digital R&D paradigm.

  • “Necessity is the mother of invention” – why is AI so valuable to R&D teams?
  • How successful has innovation in the R&D space been thus far?
  • Commercialising data-driven drug discovery and development technologies

Register here →

Featuring:

Jackie Hunter | Board Member, BenevolentAI

Abraham Heifets | CEO Atomwise

Martin-Immanuel Bittner | CEO, Arctoris

Nick Scott-Ram | Chief of Strategic Development, Sensyne Health

Moderator: Bill Aronson | COO, Artificial Intelligence Research Group


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021